Presentation is loading. Please wait.

Presentation is loading. Please wait.

A PROSPECTIVE MULTICENTRE REGISTRY FOR THE ASSESSMENT OF SAFETY AND EFFICACY OF BIODEGRADABLE POLYMER COATED, PACLITAXEL ELUTING STENT LUC TM * *(BALTON,

Published byTyrone Powell Modified over 9 years ago

Similar presentations

Presentation on theme: "A PROSPECTIVE MULTICENTRE REGISTRY FOR THE ASSESSMENT OF SAFETY AND EFFICACY OF BIODEGRADABLE POLYMER COATED, PACLITAXEL ELUTING STENT LUC TM * *(BALTON,"— Presentation transcript:

1 A PROSPECTIVE MULTICENTRE REGISTRY FOR THE ASSESSMENT OF SAFETY AND EFFICACY OF BIODEGRADABLE POLYMER COATED, PACLITAXEL ELUTING STENT LUC TM * *(BALTON, POLAND) 9 th month study P. Buszman 1,2, R. Gil 3, J. Rzezniczak 4, T. Przewlocki 5, M. Kosmider 6, J. Wojcik 7, J. Janczak 8, S. Trznadel 2, L. Kinasz 2, M. Kondys 2, M. Krol 2, K. Milewski 1,2 1. Silesian Medical School, Katowice 2. American Heart of Poland, Ustron 3. Central Hospital of the Ministry of Internal Affairs, Warsaw 4. Department of Cardiology, District Hospital, Poznan 5. Institute of Cardiology, CM, JU, Kraków 6. Department of Cardiology and Cardiac Surgery, Medical School, Lodz 7. Division of Cardiology, Lublin 8. Department of Cardiology, Central Military Hospital, Warsaw

2 LIMITATIONS OF POLYMER COATED DES’s Although polymers can ensure predictable release of different drugs, in some cases they cause exaggerated inflammatory response, neointimal hyperplasia and thrombosis. Biodegradable polymer – drug eluting stents (BP- DES) are to resolve the problem of chronic vascular inflammation and late thrombosis. A new concept: after the drug and polymer are eluted, only neutral stainless steel is left in the vessel wall.

3 CHARACTERISTIC OF LUC STENT The tested stents were made of the highest quality biocompatible 316 stainless steel alloy with 0,13mm strut thickness. The coating was performed utilizing biocompatible and biodegradable polymers, whose exact composition is proprietary to Balton Company. A total amount of polymer mounted on 3,5x15mm stent does not exceed 365 µg. Paclitaxel in dose 1 μg / mm2 was chosen as a drug which inhibits cell proliferatin and thus can inhibit restenosis The composition of BMS Others: carbon, copper, phosphorus, sulphur, silicon.

4 BIODEGRADATION OF TESTED POLYMER The surface of the stent after 1 week The surface after 8 weeks Residual polymer left on the stent surface after 8 weeks The samples of stents covered with tested polymer and removed from isotonic salt solution at different time points

5 ANIMAL STUDY THE AIM: To evaluate safety and intimal hyperplasia after coronary implantation of LUC stent To assess the influence of biodegradable polymer on tested arteries RESULTS: Neointimal hyperplasia was succesfully inhibited by LUC stents at 30 days f-up. However, after 90 days the parameters of neoitnimal hyperplasia and stenosis severity were similar to BMS. Qualitative histopathological examination did not show excessively negative influence of polymer on tested artery. QCA: Late Loss

6 FIRST IN MAN STUDY Prospective, multi-center registry Warszawa Lodz Ustron Lublin Poznan Katowice Krakow Bielsko Biała

7 FIRST IN MAN STUDY Silesian Medical School, KatowiceP. BuszmanKatowice American Heart of PolandM. KondysUstron Central Hospital of the Ministry of Internal AffairsR. GilWarszawa Department of Cardiology, District HospitalJ. RzezniczakPoznan American Heart of PolandL. KinaszBielsko Institute of Cardiology, CM, JU, Kraków T. PrzewlockiKrakow Department of Cardiology and Cardiac SurgeryM. KosmiderLodz Division of CardiologyJ. WojcikLublin Department of Cardiology, Central Military HospitalJ. JanczakWarszawa Silesian Medical School, KatowiceP. BuszmanKatowice American Heart of PolandM. KondysUstron Central Hospital of the Ministry of Internal AffairsR. GilWarszawa Department of Cardiology, District HospitalJ. RzezniczakPoznan American Heart of PolandL. KinaszBielsko Institute of Cardiology, CM, JU, Kraków T. PrzewlockiKrakow Department of Cardiology and Cardiac SurgeryM. KosmiderLodz Division of CardiologyJ. WojcikLublin Department of Cardiology, Central Military HospitalJ. JanczakWarszawa

8 FIRST IN MAN STUDY Principle Investigator: Pawel Buszman, MD, FESC, FSCAI Clinical Events Committee: Mariusz Gasior Ciecwierz Leszek Angiographic Core Lab: Core Imaging Analysis Laboratory Krakow Cardiovascular Research Institute

9 FIRST IN MAN STUDY Material and method: Enrollment of 113 patients with:  de-novo lesion in native coronary artery  vessel diameter 2.8 – 4.0 mm  lesion length  18 mm  stenosis ≥ 50% and ≤100% Dual antiplatelet therapy required for 9months Period of implantation: 07/2005 – 11/2005

10 FIRST IN MAN STUDY Clinical endpoints: MACE after 30 days, 6 and 9 months Angiographic endpoints: Late loss Restenosis rate F-up visits after 30 days, then subsequently after 3 and 6 months to define MACE rate. 9-months control coronarography

11 PATIENT CHARACTERISTICS Male83 [73,4 %] Hypercholesterolaemia68 [60,2 %] Family history27 [23,8 %] Smoking64 [56,6%] Diabetes24 [21,2 %] Hypertension80 [70,8 %] Pior MI43 [38,1 %] Stable angina98 [86,7 %] Unstable angina10 [8,8 %] STEMI, NSTEMI 2 [1,8 %] Vessel disease

12 ANGIOGRAPHIC DATA LAD RCA 37% 41%41%41%41% LCx 17% others 5% Lesion type C 9% B2 39% A 10% Direct stenting: n = 74 Predilatation:n = 31 Success rate:100% B1 42% Calcification (moderate to severe)10% Thrombus1% Eccentric70% Angulation <45 0 93% 45-90 0 7% Lesion location

13 CLINICAL OUTCOME 0-1 month1-6 month6-9 monthTotal 0-9 month Any MACE1113 (2.7%) Death0000 MI0101 (0,9%) Acute stent thrombosis1001 (0,9%) Clinically driven TLR1113 (2,7%)

14 ANGIOGRAPHIC DATA Before procedure After procedure Follow up 9months (n=90) Reference diameter (mm) 2.90 ± 0.443.07 ± 0.412.98 ± 0.4 MLD (mm)1.09 ± 0.452.65 ± 0.362.21 ± 0.6 Lesion length (mm)13.94 ± 4.715.9 ± 4.216.0± 4.2 % DS.62.8 ± 1413.8 ± 1027.1±18.4 Acute Gain (mm)-1.55 ± 0.55- Late loss (mm)--0.45 ±0.5

15 DISTRIBUTION OF STENOSIS SEVERITY Percent diameter stenosis after 9 months

16 BINARY RESTENOSIS RATE AT 9 MONTHS 10% Focal4 In-stent4 Diffuse1 Occlusive0 Patterns of in-stent restenosis (Mehran classification) Risk of restenosis in relation to type of lesion 11,1% 15,8% 5,7% 0% Restenosis rate

17 LUC vs OTHER DES’s Comparison Among DES Trials Late Loss Comparison Among DES TRIALS Binary Restenosis (In Stent)

18 LUC vs OTHER DES’s Comparison Among DES Trials MACE

19 SUMMARY Excellent procedural outcome with device success 100% Excellent procedural outcome with device success 100% Low MACE rate over 9 months after implantation (2.7%) Low MACE rate over 9 months after implantation (2.7%) Favorable late (9 months) angiographic results: Favorable late (9 months) angiographic results: - Binary restenosis 10,0% - Late loss 0.45 mm

Download ppt "A PROSPECTIVE MULTICENTRE REGISTRY FOR THE ASSESSMENT OF SAFETY AND EFFICACY OF BIODEGRADABLE POLYMER COATED, PACLITAXEL ELUTING STENT LUC TM * *(BALTON,"

Similar presentations

SPIRIT IV A Prospective, Randomized Trial Comparing an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease.

SPIRIT IV A Prospective, Randomized Trial Comparing an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease.
Copyleft Clinical Trial Results. You Must Redistribute Slides PEPCAD II ISR Study Paclitaxel-eluting devices: randomized comparison of the SeQuent™ please.

Copyleft Clinical Trial Results. You Must Redistribute Slides PEPCAD II ISR Study Paclitaxel-eluting devices: randomized comparison of the SeQuent™ please.
Call for CASES Motaz AbuSamra Krzysztof Milewski CCU, Upper-Silesian Center of Cardiology, Silesian Medical School, Katowice, Poland Head of Department:

Call for CASES Motaz AbuSamra Krzysztof Milewski CCU, Upper-Silesian Center of Cardiology, Silesian Medical School, Katowice, Poland Head of Department:
“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:
M.Unverdorben; ACC March 2008 Martin Unverdorben Rotenburg/Fulda, Germany and Richmond, VA, USA Clinical Research Institute, Center for Cardiovascular.

M.Unverdorben; ACC March 2008 Martin Unverdorben Rotenburg/Fulda, Germany and Richmond, VA, USA Clinical Research Institute, Center for Cardiovascular.
CREATE Multi-Center Clinical Registry 9-month Angiographic and 12-month Clinical Results Yaling Han MD, FSCAI On behalf of the CREATE investigators ACC.

CREATE Multi-Center Clinical Registry 9-month Angiographic and 12-month Clinical Results Yaling Han MD, FSCAI On behalf of the CREATE investigators ACC.
EXCELLA BD Randomized Trial 12-month Results

EXCELLA BD Randomized Trial 12-month Results
3rd CEEGI Advisory Board1 Resolute in the DES era: Indications & Limitations Georgios I. Papaioannou, MD, MPH, FACC, FSCAI Athens Medical Center Cardiac.

3rd CEEGI Advisory Board1 Resolute in the DES era: Indications & Limitations Georgios I. Papaioannou, MD, MPH, FACC, FSCAI Athens Medical Center Cardiac.
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)

Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,

DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
Call for CASES Staged PCI in a patient with multivessel coronary disease disqualified from CABG. Pawel Buszman, MD, FESC, FSCAI Marcin Debinski, MD Krzysztof.

Call for CASES Staged PCI in a patient with multivessel coronary disease disqualified from CABG. Pawel Buszman, MD, FESC, FSCAI Marcin Debinski, MD Krzysztof.
Call for CASES Leszek D. Stachaczyk, MD Pawel Buszman, MD, FESC, FSCAI American Heart of Poland, Ustroñ, Poland & CCU, Upper-Silesian Center of Cardiology,

Call for CASES Leszek D. Stachaczyk, MD Pawel Buszman, MD, FESC, FSCAI American Heart of Poland, Ustroñ, Poland & CCU, Upper-Silesian Center of Cardiology,
Clinical Result Overview

Clinical Result Overview
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.

Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.

As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
Meredith ● EVOLVE Primary Endpoint ● TCT 2011 ● San Francisco, CA Slide 1 Meredith ● EVOLVE overview ● TCT 2010 ● Washington, DC Slide 1 Clinical and Angiographic.

Meredith ● EVOLVE Primary Endpoint ● TCT 2011 ● San Francisco, CA Slide 1 Meredith ● EVOLVE overview ● TCT 2010 ● Washington, DC Slide 1 Clinical and Angiographic.
TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.

TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.

CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.

Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®

The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®

Similar presentations

Ads by Google